Comorbidities in psoriasis

Indian Journal of Dermatology, Venereology and Leprology

Volumn 79, Issue SUPPL. 1, 2013, Pages

  Aurangabadkar, Sanjeev ^a  

^a Skin and Laser Clinic ^*  (India)

Author keywords

Cardiovascular disease; comorbidities; metabolic syndrome; psoriasis

Indexed keywords

METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADAPTIVE IMMUNITY; ALCOHOL CONSUMPTION; ANXIETY; ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY CALCIFICATION; CROHN DISEASE; DEPRESSION; DIABETES MELLITUS; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERTENSION; INNATE IMMUNITY; LONGEVITY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PSORIASIS; PSORIATIC ARTHRITIS; SLEEP DISORDERED BREATHING; SOCIAL INTERACTION; ULCERATIVE COLITIS;

CARDIOVASCULAR DISEASES; COMORBIDITY; CROHN DISEASE; FATTY LIVER; HUMANS; LONGEVITY; MENTAL DISORDERS; METABOLIC SYNDROME X; NEOPLASMS; PSORIASIS;

EID: 84883163836     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.115506     Document Type: Article

References (55)

1. Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol 2012;11:s5-10.
2. Fernandez-Torres RM, Paradela S, Fonseca E. Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. J Nutr Health Aging 2012;16:586-91.
3. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: Results from the National Health and Nutrition Examination Survey, 2003- 2006. Arch Dermatol 2011;147:419-24.
4. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: Epidemiology and pathophysiology. Curr Opin Rheumatol 2008;20:416-22.
5. Gisondi P, Del Giglio M, Cozzi A, Girolomoni G. Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther 2010;23:155-9.
6. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology 2006;212:123-7.
7. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: A review. Australas J Dermatol 2004;45:155-9.
8. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383-92.
9. Rakhesh SV, D'Souza M, Sahai A. Quality of life in psoriasis: A study from south India. Indian J Dermatol Venereol Leprol 2008;74:600-6.
10. Gaikwad R, Deshpande S, Raje S, Dhamdhere DV, Ghate MR. Evaluation of functional impairment in psoriasis. Indian J Dermatol Venereol Leprol 2006;72:37-40.
11. Hayes J, Koo J. Psoriasis: Depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010;23:174-80.
12. Kimball AB, Wu EQ, Guérin A, Yu AP, Tsaneva M, Gupta SR, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol 2012;67:651-7.
13. Golpour M, Hosseini SH, Khademloo M, Ghasemi M, Ebadi A, Koohkan F, et al. Depression and anxiety disorders among patients with psoriasis: A Hospital-Based Case-Control study. Dermatol Res Pract 2012;2012:381905.
14. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000;14:267-71.
15. Scharloo M, Kaptein AA, Weinman J, Bergman W, Vermeer BJ, Rooijmans HG. Patients' illness perceptions and coping as predictors of functional status in psoriasis: A 1-year follow-up. Br J Dermatol 2000;142:899-907.
16. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846-50.
17. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol 2007;57:347-54.
18. Cassano N, Vestita M, Apruzzi D, Vena GA. Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. Int J Dermatol 2011;50:1323-31.
19. Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo and psoriasis: A comparative study from India. J Dermatol 2001;28:424-32.
20. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol 2010;76:595-601.
21. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35.
22. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: A population-based study. Br J Dermatol 2011;165:1037-43.
23. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - A new worldwide definition. Lancet 2005;366:1059-62.
24. Liu J, Grundy SM, Wang W, Smith SC Jr, Vega GL, Wu Z, et al. Ethnic-specific criteria for the metabolic syndrome: Evidence from China. Diabetes Care 2006;29:1414-6.
25. Sterry W, Strober BE, Menter A, International Psoriasis Council. Obesity in psoriasis: The metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649-55.
26. Pietrzak A, Chodorowska G, Szepietowski J, Zalewska-Janowska A, Krasowska D, Hercogová J. Psoriasis and serum lipid abnormalities. Dermatol Ther 2010;23:160-73.
27. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol 2012;39:212-8.
28. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther 2010;23:137-43.
29. Duarte GV, Follador I, Cavalheiro CM, Silva TS, Oliveira Mde F. Psoriasis and obesity: Literature review and recommendations for management. An Bras Dermatol 2010;85:355-60.
30. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010;23:114-8.
31. Duarte GV, Oliveira Mde F, Cardoso TM, Follador I, Silva TS, Cavalheiro CM, et al. Association between obesity measured by different parameters and severity of psoriasis. Int J Dermatol 2013;52:177-81.
32. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-7.
33. Vena GA, Vestita M, Cassano N. Psoriasis and cardiovascular disease. Dermatol Ther 2010;23:144-51.
34. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007;190:1-9.
35. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012;148:1244-50.
36. Madanagobalane S, Anandan S. The increased prevalence of nonalcoholic fatty liver disease in psoriatic patients: A study from South India. Australas J Dermatol 2012;53:190-7.
37. Binus AM, Han J, Qamar AA, Mody EA, Holt EW, Qureshi AA. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol 2012;26:644-50.
38. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-6.
39. Ludvigsson JF, Lindelöf B, Zingone F, Ciacci C. Psoriasis in a nationwide cohort study of patients with celiac disease. J Invest Dermatol 2011;131:2010-6.
40. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-201.
41. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J Invest Dermatol 2003;120:211-6.
42. Frentz G, Olsen JH. Malignant tumours and psoriasis: A follow-up study. Br J Dermatol 1999;140:237-42.
43. Chiang YY, Lin HW. Association between psoriasis and chronic obstructive pulmonary disease: A population-based study in Taiwan. J Eur Acad Dermatol Venereol 2012;26:59-65.
44. Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: A casecontrol study. Br J Dermatol 2008;159:956-60.
45. Bañares A, Hernández-García C, Fernández- Gutiérrez B, Jover JA. Eye involvement in the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:771-84.
46. Lima FB, Abalem MF, Ruiz DG, Gomes Bde A, Azevedo MN, Moraes HV Jr, et al. Prevalence of eye disease in Brazilian patients with psoriatic arthritis. Clinics (Sao Paulo) 2012;67:249-53.
47. Reich K. The concept of psoriasis as a systemic inflammation: Implications for disease management. J Eur Acad Dermatol Venereol 2012;26:3-11.
48. Wakkee M, Meijer W, Neumann HA, Herings RM, Nijsten T. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: A 5-year prevalence study. Acta Derm Venereol 2009;89:476-83.
49. Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halevy S. Drug exposure and psoriasis vulgaris: Case-control and case-crossover studies. Acta Derm Venereol 2005;85:299-303.
50. Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: A study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008;159:1116-23.
51. Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: Atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009;161:1-7.
52. Späh F. Inflammation in atherosclerosis and psoriasis: Common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008;159:10-7.
53. Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ 2010;340:b5666.
54. Pietrzak A, Bartosinska J, Chodorowska G, Szepietowski JC, Paluszkiewicz P, Schwartz RA. Cardiovascular aspects of psoriasis: An updated review. Int J Dermatol 2013;52:153-62.
55. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42.